Background: Faecal calprotectin decreases during exclusive enteral nutrition in children with active Crohn's disease. It is unknown how faecal calprotectin changes during food re-introduction and the influence of maintenance enteral nutrition.
| INTRODUC TI ON
As Crohn's disease remains incurable, current therapy aims to induce and maintain clinical remission and, when possible, intestinal mucosal and transmural healing. 2 Exclusive enteral nutrition (EEN) is a liquid-only formula diet which is highly effective in achieving clinical remission in paediatric Crohn's disease. 3 EEN is recommended as the first line treatment for active luminal Crohn's disease in children with up to 89% of patients achieving clinical remission when placed on EEN for 8 weeks. 4, 5 Reviews and meta-analyses have shown that EEN is as effective as oral corticosteroids in inducing clinical remission, in paediatric patients. It also has the added benefits of mucosal healing in a significant proportion of patients plus improvement in the overall nutritional status of patients. [6] [7] [8] [9] Achieving complete mucosal healing after a course of EEN has been associated with reduced relapse rates and complications in the medium term. 2 While the use of enteral nutrition as induction therapy of active Crohn's disease is well established, use of partial enteral nutrition, as a maintenance therapy (maintenance enteral nutrition or MEN), is less well studied. 10 Previous research suggested that MEN may be effective in prolonging periods of clinical remission. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, these studies have generally been of retrospective design, lacked robust assessment of MEN compliance and have not examined changes in gut markers of colonic inflammation.
We have previously described the effect that EEN has on faecal calprotectin, in children with active Crohn's disease during induction treatment with EEN, which has subsequently been replicated by others. 23, 24 EEN reduces the pre-treatment concentration of faecal calprotectin by an average of 48% nevertheless, less than 20%-25% of those who have completed a successful course will have a measurement of FC below 250 mg/kg. 24 In our previous research we also have described that faecal calprotectin levels increased rapidly in patients within 4 months of food reintroduction. 23 Hence, it is of interest to study how quickly faecal calprotectin rises during the early and medium phase of food reintroduction in patients who completed a successful course of EEN, and whether MEN use can modify this effect. Furthermore, the concurrent change in cytokines paralleling changes in clinical and biochemical parameters has only been described in a few studies, contrasting with the well-documented changes in patients undergoing biologic treatment. [25] [26] [27] [28] The aim of the current study was to determine short and medium-term changes in faecal calprotectin during food reintroduction, following induction of remission with EEN, and to explore the effectiveness of MEN to influence these changes in addition to risk of subsequent clinical relapse.
| ME THODS

| Patients
Patients with suspected IBD who attended the Royal Hospital for Children, Glasgow and neighbouring district general hospitals, were recruited prospectively between October 2014 and May 2017.
Diagnosis was based on established radiological, histological and endoscopic guidelines. 29 Disease behaviour and anatomical location were classified using the Paris classification. 30 Patients who were subsequently diagnosed with Crohn's disease were followed up and samples were collected throughout their EEN course and during food re-introduction. Patients who had already received a diagnosis of Crohn's disease and were undergoing a repeat course of EEN were also recruited. Patients who had received antibiotics in the preceding month were excluded. Written assent or consent was taken from participants and their carers according to good clinical practice. The study was approved by the NHS West of Scotland Research Ethics Committee (14/WS/1004) and was registered in clinicaltrials.gov (NCT02341248).
| Exclusive enteral nutrition and food reintroduction
Patients were treated for 8 weeks with a polymeric, casein-based formula (Modulen IBD). Paediatric dieticians calculated the feed volume to provide the energy requirements for each child based
Conclusions:
The effect of exclusive enteral nutrition on faecal calprotectin is diminished early during food reintroduction. Maintenance enteral nutrition at ~18% of energy intake is associated with a lower faecal calprotectin at the early phase of food reintroduction but is ineffective in maintaining longer term remission. on the UK age and sex recommendations. 31 Children who were undernourished (BMI Z-score < −2 SD) were prescribed a 10% higher energy intake while on EEN. No other food was allowed during the EEN course, with the exception of black tea or coffee, water, or a sodium-benzoate free carbonated sugar-containing lemon and lime soft drink (7UP), clear mints and syrup flavouring. Patients were encouraged to consume EEN orally, however, if patients were unable to take their prescribed formula volumes within the first 3 days, patients were then switched to nasogastric tube feeding. While on EEN, patients received regular nurse and dietetic weekly support calls and were reviewed in the clinic 4 weeks post initiation.
If the participant did not clinically improve or deteriorated within the initial treatment period, EEN therapy was discontinued and an alternative induction treatment was commenced, usually oral corticosteroids.
Patients who successfully completed their course of EEN and entered clinical remission (defined as a decrease in weighted paediatric Crohn' wPCDAI <12.5) were encouraged to continue using their enteral formula as an oral supplement (MEN), consuming approximately 20%-25% of their total EEN volume, in addition to their free habitual diet. Patients had a rapid food reintroduction, with no specific dietary recommendations given by the members of the clinical team after the end of EEN, other than to offer MEN.
| Clinical assessment
Measurements of anthropometry were obtained and calculated as Z-scores using the UK-WHO growth charts. 32 C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum albumin and haemoglobin were measured at EEN initiation, end of treatment and at routine clinic appointments post-EEN. Clinical disease activity was defined using the weighted paediatric Crohn's disease activity index (wPCDAI). 33 Use of maintenance drug therapies were also recorded.
| Faecal calprotectin measurements
Fresh faecal samples to measure faecal calprotectin were collected from children at enrolment, before they began treatment with EEN.
Two subsequent samples were scheduled to be collected during pa- ELISA kit according to the manufacturer's instructions and as described previously. 34 
| Cytokine profile changes during EEN
Blood samples were collected in EDTA tubes and plasma separated within 2 hours. The concentration of 19 inflammatory cytokines was analysed using the U-PLEX Proinflam Combo 1 (IFN-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α) (K15049K) and the U-PLEX TH17 Combo (IL-17A, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-27, IL-31, IL-33) (K15075K) assay kits (Meso Scale Discovery).
| Dietary assessment
During food re-introduction and prior to sample collection, at 2 weeks and 2 months post-EEN, the energy intake of participants was estimated using 3-day estimated weight food diaries. Household measures were used to estimate portion size. Patients were asked to record compliance with MEN and the exact amount consumed on the same food diaries. These diaries were analysed into WinDiets 10 Software Suite (version 10; Robert Gordon University), to calculate energy intake.
Associations were explored between faecal calprotectin and both the volume and energy intake attributable to MEN. Energy intake was expressed in kcals, as percentage of patient's estimated average energy requirement (EAR) and as a percentage of energy intake. No MEN intake was assigned to patients who returned a food diary without reporting use of MEN.
| Rates of remission and relapse within 1-year post EEN
Patients were followed up to a maximum of 12 months, following completion of EEN. Clinical relapse was defined as deterioration of disease requiring a further induction therapy as dictated by the clinical caring team.
| Statistics
Continuous data are displayed with median and interquartile range, unless otherwise stated. Differences in rates of remission based on disease location were evaluated using a χ 2 test. Two-sample t tests were performed to compare differences between two independent groups in patient characteristics. Mann-Whitney U tests were performed to explore differences in proportional changes in faecal calprotectin during food reintroduction grouped together (Table S1 ).
| RE SULTS
| Patient population
Sixty-six (97%) patients were initially treated with EEN, with one newly diagnosed patient starting directly on anti-TNF therapy, and another with mild symptoms starting treatment with budesonide enemas. Of the 66 patients to start EEN, 53 (80%) completed at least 42 days (median, 55 days; Q1: 45, Q3: 56). Fourteen (14/66, [21%]) patients required nasogastric tube feeding, while the remaining 52/66 (79%) consumed EEN orally.
Clinical remission was achieved in 41 (62%) patients ( Figure 1 ).
Remission on EEN was independent of disease location (P = 0.25) (Table S2 ). Of the 25 patients not to achieve remission on EEN, 13 discontinued treatment (due to intolerance or symptom deterioration). The other 12 children completed an 8-week course of EEN; of whom three achieved clinical response and the remaining nine patients did not show clinical response using wPCDAI definitions.
| Systemic inflammatory markers changes during EEN
Sixty-three (63/66 [95%]) patients had systemic inflammatory markers available at treatment initiation of whom 40 (65%) had at least one inflammatory marker (CRP, ESR, albumin) abnormal.
These inflammatory markers improved when patients completed EEN, with 12/40 (30%) having at least one marker outside the normal range. Among those who entered clinical remission or clinically improved, and whose blood measurements were available, 22/32 (69%) patients had all normal inflammatory makers (Table   S1 ).
| Faecal calprotectin concentration changes during EEN
From the 66 patients who started on EEN, a faecal sample was obtained for baseline faecal calprotectin measurement in 53 (80%).
Median faecal calprotectin at the start of treatment was 1433 mg/ 
| Cytokine profile changes during EEN
Prior to EEN initiation, no differences in cytokine concentration were observed between responders and non-responders. Using (Table S3 ). There was no change to cytokine levels in patients who did not achieve clinical remission.
| FC changes during the early food reintroduction phase
A faecal sample was obtained at a median of 17 days (14, 21) P < .001). However, there was no difference when compared to the early food reintroduction (P = 0.25) or medium food reintroduction (P = 0.19) ( Figure 2 ). The increase in faecal calprotectin during food re-introduction preceded changes to other disease activity markers (including wPCDAI, ESR and albumin) which remained similar to values at the end of EEN (Table S1 ). (Figure 3 ).
| MEN and changes in FC during food reintroduction
In the same, early phase of food reintroduction, there was an inverse correlation between faecal calprotectin and MEN when ex- Figure S2 ). This effect was lost during the medium-and long-term periods of food reintroduction. Figure S3 ). There was no difference in relapse rates at (Figure 4 ). 
| Relapse rates at 1-year post EEN
| Effect of other maintenance treatments
| D ISCUSS I ON
EEN continues to be the only established dietary treatment to induce remission in active paediatric Crohn's disease. 3 It has the added benefit over corticosteroids of improving nutritional status and has higher rates of mucosal healing. The results of this study reflect those published in the literature, with the largest decrease in FC occurring within the first 4 weeks of treatment, and a slower yet persistent decrease during the second half of treatment. 8, 23 The observed decrease in inflammatory cytokine expression It has also been shown that faecal calprotectin reverts to pretreatment levels within 4 months post-EEN, and that up to 55% of patients in clinical remission can have a raised faecal calprotectin. 23, 38 Complementing this previous work, this more detailed study demonstrated that the rise in FC post EEN to pre-treatment levels occurs more rapidly than previously recognised. 23 We show that a significant rise in faecal calprotectin is apparent within just 17 days The lack of short and long-term compliance on MEN as reported in this study also highlights adherence challenges that patients with CD face and perhaps taste fatigue with MEN. There are many conflicting reports on the utility of MEN as a maintenance therapy. We have previously published a retrospective analysis showing up to 50% of patients who used MEN as their sole maintenance therapy remained in remission within a 1-year follow-up. 11 This was similar to the response obtained in patients using azathioprine (azathioprine alone: 65%; azathioprine and MEN combined: 67%), and significantly better than those using no maintenance therapy (15%).
While the results from this earlier study suggested that MEN may be as effective as azathioprine in maintaining remission, it did not have a robust marker of compliance to MEN, as the current study did, making it difficult to assess patient's continued compliance during the length of the study, nor did it assess gut inflammation, as this study did. In this study using more detailed analysis, using patients' recorded MEN use as well as measuring faecal calprotectin, we failed to replicate these previous results.
Another retrospective study, in which MEN was provided at 30% of EAR, also did not find the use of MEN to be associated with longer periods of remission, with 78% of patients who used MEN and 77% of patients who remained on habitual diet relapsing within 1 year. 18 Of note however, EEN followed by MEN did have improved remission rates in the short term (6 months) and some of the patients in the study received MEN after a course of steroids rather than EEN.
The most compelling evidence to date for the use of MEN remains two RCTs in adults in Japan. 40, 41 The first study compared MEN use against patients following their free habitual diet. The authors found MEN to be associated with a lower incidence of clinical relapse during one year of follow-up. 40 However, this study differs from this and previous reports as authors delivered MEN using elemental formula via nasogastric tube feeding, at 50% of patient's daily energy intake, at least twice as much as the current study. More recently, a second group from Japan have shown MEN at 50% using elemental formula to be as effective as 6-mercaptopurine, in maintaining remission in a cohort of adult IBD patients in an RCT with a 2-year follow-up. 41 Other groups have also reported on the clinical efficacy of MEN when recommended at high volumes of ~50% EAR. 42 The heterogeneity between studies and lack of a prospective RCT study in children remains a significant limitation in this area.
While our study is not an RCT, we have attempted to prospectively study the effect of MEN while at the same time assessing its compliance with self-reported weighted food diaries, a caveat not often captured within the existing literature. 11, 18, 45, 46 With only half of the patients returning a food diary in which to assess MEN compliance this remains a limitation in our study but is useful to highlight many patients who are "prescribed" MEN do not actually take it, suggesting that better reinforcement from the treating team may help improve compliance.
As the beneficial effects of MEN in our study are associated with a reduced faecal calprotectin during the early period of food The mechanism of action for EEN, as with MEN, remains to be fully clarified, though several studies have implicated the importance of the gut microbiome. [49] [50] [51] [52] To our knowledge there is only one study exploring the influence of MEN on the microbiome.
However, as this was carried out in only two patients, with varying sample time-points, it is difficult to place these results in the larger context, due to the inherent heterogeneity between subject's microbiome. 49 Our data on clinical response to treatment are similar to previous reports but while patient's weight increased too, the magnitude of this effect was not as large as published historically. 5, 53 This may be explained in part by our patients not having as low z-scores suggesting improved detection and earlier diagnosis. The weight gain we observed in this study is similar to other published literature. 5, 44 We have demonstrated that changes in patient's weight during the first 4 weeks of treatment with EEN predicted which patients would enter clinical remission by the end of EEN.
While this is very similar to the prediction validity using changes in faecal calprotectin during the same period, using weight change as a predictor creates a circular argument with assessing disease improvement using wPCDAI. We were unable to perform this analysis using changes in systemic markers of inflammation (CRP, ESR, inflammatory cytokines) as it is not the practice in our centre to routinely venepuncture patients at the midpoint of EEN, who are responding well clinically.
In conclusion, the current study confirms previous observa- 
